These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2303717)

  • 1. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
    Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
    J Immunol; 1990 Feb; 144(4):1538-43. PubMed ID: 2303717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
    Ramos OF; Patarroyo M; Yefenof E; Klein E
    J Immunol; 1989 Jun; 142(11):4100-4. PubMed ID: 2565929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
    Ramos OF; Kai C; Yefenof E; Klein E
    J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments.
    Ramos OF; Nilsson B; Nilsson K; Eggertsen G; Yefenof E; Klein E
    Cell Immunol; 1989 Apr; 119(2):459-69. PubMed ID: 2522826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B; Lebow LT; Bradley TP
    J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killing of human tumor cells by antibody C3b conjugates and human complement.
    Reiter Y; Fishelson Z
    Targeted Diagn Ther; 1989; 2():119-35. PubMed ID: 2519543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
    Vetvicka V; Thornton BP; Wieman TJ; Ross GD
    J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules.
    Schmidt RE; Caulfield JP; Michon J; Hein A; Kamada MM; MacDermott RP; Stevens RL; Ritz J
    J Immunol; 1988 Feb; 140(3):991-1002. PubMed ID: 3276787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
    Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
    J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
    Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
    J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.
    Scott CF; Bolender S; McIntyre GD; Holldack J; Lambert JM; Venkatesh YP; Morimoto C; Ritz J; Schlossman SF
    J Immunol; 1989 Jun; 142(11):4105-12. PubMed ID: 2565930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
    Ramos OF; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):975-9. PubMed ID: 3111863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells.
    Roozemond RC; Bonavida B
    J Immunol; 1985 Apr; 134(4):2209-14. PubMed ID: 3855929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukemia-derived cell lines and clones as models for mechanistic analysis of natural killer cell-mediated cytotoxicity.
    Zarcone D; Tilden AB; Friedman HM; Grossi CE
    Cancer Res; 1987 May; 47(10):2674-82. PubMed ID: 2436754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of altered membrane structure on NK cell-mediated cytotoxicity. II. Conversion of NK-resistant tumor cells into NK-sensitive targets upon fusion with liposomes containing NK-sensitive membranes.
    Roozemond RC; van der Geer P; Bonavida B
    J Immunol; 1986 May; 136(10):3921-9. PubMed ID: 3701064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
    Katz JD; Mitsuyasu R; Gottlieb MS; Lebow LT; Bonavida B
    J Immunol; 1987 Jul; 139(1):55-60. PubMed ID: 3584988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.